BR112023023715A2 - Pluralidade de partículas compreendendo tasquinimod, composição farmacêutica, unidade de dosagem farmacêutica, uso da pluralidade de partículas ou da composição farmacêutica, e, método para o tratamento do câncer - Google Patents
Pluralidade de partículas compreendendo tasquinimod, composição farmacêutica, unidade de dosagem farmacêutica, uso da pluralidade de partículas ou da composição farmacêutica, e, método para o tratamento do câncerInfo
- Publication number
- BR112023023715A2 BR112023023715A2 BR112023023715A BR112023023715A BR112023023715A2 BR 112023023715 A2 BR112023023715 A2 BR 112023023715A2 BR 112023023715 A BR112023023715 A BR 112023023715A BR 112023023715 A BR112023023715 A BR 112023023715A BR 112023023715 A2 BR112023023715 A2 BR 112023023715A2
- Authority
- BR
- Brazil
- Prior art keywords
- particles
- pharmaceutical composition
- dosage unit
- tasquinimod
- pharmaceutical
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 title abstract 3
- 229950001899 tasquinimod Drugs 0.000 title abstract 3
- 239000012458 free base Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Powder Metallurgy (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21175623 | 2021-05-25 | ||
| PCT/EP2022/063887 WO2022248401A1 (en) | 2021-05-25 | 2022-05-23 | A plurality of tasquinimod particles and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023023715A2 true BR112023023715A2 (pt) | 2024-02-20 |
Family
ID=76098832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023023715A BR112023023715A2 (pt) | 2021-05-25 | 2022-05-23 | Pluralidade de partículas compreendendo tasquinimod, composição farmacêutica, unidade de dosagem farmacêutica, uso da pluralidade de partículas ou da composição farmacêutica, e, método para o tratamento do câncer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12485095B2 (enExample) |
| EP (1) | EP4346773B1 (enExample) |
| JP (1) | JP7874664B2 (enExample) |
| KR (1) | KR20240012436A (enExample) |
| CN (1) | CN117295492A (enExample) |
| AU (1) | AU2022281056A1 (enExample) |
| BR (1) | BR112023023715A2 (enExample) |
| CA (1) | CA3218977A1 (enExample) |
| ES (1) | ES3048983T3 (enExample) |
| IL (1) | IL308542A (enExample) |
| MX (1) | MX2023013301A (enExample) |
| PL (1) | PL4346773T3 (enExample) |
| WO (1) | WO2022248401A1 (enExample) |
| ZA (1) | ZA202311594B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025228998A1 (en) * | 2024-04-30 | 2025-11-06 | Institut National de la Santé et de la Recherche Médicale | Use of hdac4 inhibitors for the treatment of melanoma |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| CN104016951B (zh) * | 2010-03-19 | 2016-07-13 | 北京强新生物科技有限公司 | 靶向癌症干细胞的化合物和组合物 |
| WO2012004338A1 (en) | 2010-07-09 | 2012-01-12 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| TWI686212B (zh) * | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
| WO2015160696A1 (en) | 2014-04-14 | 2015-10-22 | Yale University | Compositions and methods of inhibiting histone deacetylases |
| EP3041472B1 (en) | 2014-09-23 | 2017-02-01 | Active Biotech AB | Quinoline carboxamides for use in the treatment of multiple myeloma |
| BR112017009854B1 (pt) * | 2014-11-19 | 2022-08-23 | Active Biotech Ab | Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| WO2018105943A1 (ko) | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
| WO2018208993A1 (en) * | 2017-05-09 | 2018-11-15 | Dignity Health | Drug delivery composition and method of fabrication |
| US20230293512A1 (en) | 2020-07-23 | 2023-09-21 | Erasmus University Medical Center Rotterdam | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| WO2022152902A1 (en) | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
-
2022
- 2022-05-23 KR KR1020237042849A patent/KR20240012436A/ko active Pending
- 2022-05-23 WO PCT/EP2022/063887 patent/WO2022248401A1/en not_active Ceased
- 2022-05-23 PL PL22730773.3T patent/PL4346773T3/pl unknown
- 2022-05-23 US US18/289,738 patent/US12485095B2/en active Active
- 2022-05-23 AU AU2022281056A patent/AU2022281056A1/en active Pending
- 2022-05-23 ES ES22730773T patent/ES3048983T3/es active Active
- 2022-05-23 CN CN202280034543.8A patent/CN117295492A/zh active Pending
- 2022-05-23 JP JP2023570225A patent/JP7874664B2/ja active Active
- 2022-05-23 EP EP22730773.3A patent/EP4346773B1/en active Active
- 2022-05-23 CA CA3218977A patent/CA3218977A1/en active Pending
- 2022-05-23 BR BR112023023715A patent/BR112023023715A2/pt unknown
- 2022-05-23 MX MX2023013301A patent/MX2023013301A/es unknown
- 2022-05-23 IL IL308542A patent/IL308542A/en unknown
-
2023
- 2023-12-18 ZA ZA2023/11594A patent/ZA202311594B/en unknown
-
2025
- 2025-11-24 US US19/399,224 patent/US20260076908A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4346773B1 (en) | 2025-07-02 |
| US20260076908A1 (en) | 2026-03-19 |
| ZA202311594B (en) | 2025-04-30 |
| ES3048983T3 (en) | 2025-12-12 |
| JP7874664B2 (ja) | 2026-06-16 |
| US20240285532A1 (en) | 2024-08-29 |
| KR20240012436A (ko) | 2024-01-29 |
| JP2024520307A (ja) | 2024-05-24 |
| PL4346773T3 (pl) | 2025-11-03 |
| MX2023013301A (es) | 2023-12-04 |
| AU2022281056A1 (en) | 2023-11-30 |
| IL308542A (en) | 2024-01-01 |
| EP4346773C0 (en) | 2025-07-02 |
| US12485095B2 (en) | 2025-12-02 |
| EP4346773A1 (en) | 2024-04-10 |
| CN117295492A (zh) | 2023-12-26 |
| WO2022248401A1 (en) | 2022-12-01 |
| CA3218977A1 (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019085A2 (pt) | Uso de agentes para tratamento de condições respiratórias | |
| MX9200992A (es) | Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion. | |
| BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
| BR112023018472A2 (pt) | Composições de psilocibina, métodos de produção e métodos de uso das mesmas | |
| BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
| NO20061325L (no) | Kombinasjon av legemidler for behandling av neoplasmer | |
| AR037629A1 (es) | Formulaciones farmaceuticas que comprenden un derivado de platino | |
| CL2024003232A1 (es) | Compuestos derivados de heteroarilo y uso para tratar el dolor. | |
| ES2109899T1 (es) | Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos. | |
| CO6280475A2 (es) | Metodo para tratar la deficiencia de vitamina b12 | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
| CL2024003231A1 (es) | Compuestos derivados de heteroarilo y uso para tratar el dolor. | |
| BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| NO20055891L (no) | Kinazolinderivater som aurorakinaseinhibitorer | |
| BR0308957A (pt) | Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação | |
| BRPI0715609A2 (pt) | Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica | |
| AR026254A1 (es) | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 | |
| BR0007452A (pt) | Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação | |
| BR112022012081A2 (pt) | Método para tratar câncer, kit, e, uso de uma combinação terapêutica | |
| AR052830A1 (es) | Regimen de cladribina para tratar esclerosis multiple | |
| BR0315609A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica |